International Assets Investment Management LLC Grows Position in IDEXX Laboratories, Inc. $IDXX

International Assets Investment Management LLC increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 811 shares of the company’s stock after acquiring an additional 39 shares during the quarter. International Assets Investment Management LLC’s holdings in IDEXX Laboratories were worth $435,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Stratos Wealth Partners LTD. lifted its stake in IDEXX Laboratories by 1.7% in the second quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock worth $564,000 after acquiring an additional 18 shares during the period. Red Spruce Capital LLC raised its holdings in IDEXX Laboratories by 1.1% in the second quarter. Red Spruce Capital LLC now owns 1,701 shares of the company’s stock worth $912,000 after purchasing an additional 19 shares in the last quarter. Rise Advisors LLC raised its holdings in IDEXX Laboratories by 3.9% in the second quarter. Rise Advisors LLC now owns 562 shares of the company’s stock worth $301,000 after purchasing an additional 21 shares in the last quarter. Harbour Investments Inc. raised its holdings in IDEXX Laboratories by 27.3% in the second quarter. Harbour Investments Inc. now owns 98 shares of the company’s stock worth $53,000 after purchasing an additional 21 shares in the last quarter. Finally, Blue Trust Inc. raised its holdings in IDEXX Laboratories by 14.2% in the second quarter. Blue Trust Inc. now owns 177 shares of the company’s stock worth $95,000 after purchasing an additional 22 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $633.78 on Thursday. The company has a market cap of $50.70 billion, a PE ratio of 52.77, a price-to-earnings-growth ratio of 4.12 and a beta of 1.58. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $688.12. The company’s 50 day moving average is $638.91 and its 200 day moving average is $554.07. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. The business had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business’s revenue was up 10.6% on a year-over-year basis. During the same quarter last year, the company earned $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Weiss Ratings reiterated a “buy (b-)” rating on shares of IDEXX Laboratories in a report on Wednesday, October 8th. Piper Sandler reiterated a “neutral” rating and issued a $700.00 target price (up from $510.00) on shares of IDEXX Laboratories in a report on Monday, August 11th. Morgan Stanley boosted their target price on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the stock an “overweight” rating in a report on Friday, August 15th. Leerink Partners upped their price objective on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, July 17th. Finally, Jefferies Financial Group started coverage on shares of IDEXX Laboratories in a report on Tuesday, July 1st. They set a “buy” rating and a $625.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $656.50.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 2,187 shares of the stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the transaction, the director directly owned 262 shares of the company’s stock, valued at $169,600.46. This trade represents a 89.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Sharon E. Underberg sold 5,450 shares of the stock in a transaction on Friday, August 8th. The shares were sold at an average price of $651.60, for a total transaction of $3,551,220.00. Following the transaction, the executive vice president directly owned 6,156 shares in the company, valued at approximately $4,011,249.60. The trade was a 46.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 54,057 shares of company stock worth $34,293,468. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.